Page last updated: 2024-08-25

rosiglitazone and Fasting Hypoglycemia

rosiglitazone has been researched along with Fasting Hypoglycemia in 18 studies

Research

Studies (18)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's12 (66.67)29.6817
2010's5 (27.78)24.3611
2020's1 (5.56)2.80

Authors

AuthorsStudies
Hamzah, MF; Muhammad, TST; Noruddin, NAA; Rosman, Z; Salin, NH; Shu-Chien, AC1
Dangi-Garimella, S1
Bebakar, WM; Brändle, M; Colagiuri, S; Kamaruddin, NA; Le Thi, TD; Marre, M; Shaw, J; Strand, J; Zdravkovic, M1
Cornelius, V; Kasliwal, R; Shakir, SA; Vlckova, V; Wilton, L1
Brath, H; Ludvik, B; Toplak, H; Wascher, T1
McGill, JB1
Depaoli, AM; Higgins, LS1
Endo, S; Fujino, Y; Fujita, Y; Honma, H; Inoue, Y; Onodera, M; Satoh, J1
Egidi, G; Popert, U1
Allen, E; Chen, R; Frederich, R; Hollander, PL; Li, J1
Cutson, JJ; Dietz, KR; Gavrilova, O; Gonzalez, FJ; Haluzik, M; Johnson, L; Matsusue, K; Nicol, CJ; Reitman, ML; Vinson, C1
Haslbeck, M; Jakob, S; Kellerer, M; Linn, T1
Cappleman, JM; Hale, PM; Kaye, W; Khutoryansky, N; McGill, J; Raskin, P; Saad, MF1
Bruce, S; Garber, A; Klein, E; Mohideen, P; Sankoh, S1
Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Gaddi, AV; Ghelfi, M; Piccinni, MN; Salvadeo, S1
Elias, AN; Lizotte, P1
Chou, HS; Ferreira-Cornwell, C; Goldstein, BJ; Jones, AR; Krebs, J; Palmer, JP; Waterhouse, B1
Donaldson, J; Garcia-Puig, J; Hamann, A; Paul, G; Stewart, M1

Reviews

3 review(s) available for rosiglitazone and Fasting Hypoglycemia

ArticleYear
Selecting among ADA/EASD tier 1 and tier 2 treatment options.
    The Journal of family practice, 2009, Volume: 58, Issue:9 Suppl Tr

    Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Glyburide; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Practice Guidelines as Topic; Prognosis; Risk Assessment; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Treatment Outcome

2009
Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.
    The American journal of clinical nutrition, 2010, Volume: 91, Issue:1

    Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Gluconeogenesis; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin Resistance; Pioglitazone; PPAR gamma; Quinolines; Retinoid X Receptors; Rosiglitazone; Sulfonamides; Thiazolidinediones

2010
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
    MMW Fortschritte der Medizin, 2003, Dec-18, Volume: 145, Issue:51-52

    Topics: 1-Deoxynojirimycin; Acarbose; Aged; Blood Glucose; Carbamates; Contraindications; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Fasting; Follow-Up Studies; Germany; Glucosamine; Glyburide; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Imino Pyranoses; Insulin; Metformin; Middle Aged; Nateglinide; Obesity; Patient Compliance; Phenylalanine; Pioglitazone; Piperidines; Practice Guidelines as Topic; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors

2003

Trials

7 trial(s) available for rosiglitazone and Fasting Hypoglycemia

ArticleYear
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
    Diabetic medicine : a journal of the British Diabetic Association, 2009, Volume: 26, Issue:3

    Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones

2009
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
    Diabetes & vascular disease research, 2011, Volume: 8, Issue:2

    Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Placebo Effect; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; United States

2011
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
    Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21, Issue:4

    Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Weight Gain

2004
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:2

    Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipid Metabolism; Male; Metformin; Middle Aged; Rosiglitazone; Tablets; Thiazolidinediones; Treatment Outcome

2006
Differential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trial.
    Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:2

    Topics: Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome

2006
Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
    Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:8

    Topics: Adiponectin; Adolescent; Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Lipids; Male; Middle Aged; Practice Guidelines as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Young Adult

2008
Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2008, Volume: 116, Issue:1

    Topics: Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Lipids; Male; Metformin; Obesity; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones

2008

Other Studies

8 other study(ies) available for rosiglitazone and Fasting Hypoglycemia

ArticleYear
Natural Compound 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al from
    Molecules (Basel, Switzerland), 2021, May-03, Volume: 26, Issue:9

    Topics: 3T3-L1 Cells; Adipocytes; Animals; Cell Differentiation; Cell Membrane; Glucose; Hepatocytes; Hypoglycemia; Insulin; Ligands; Mice; Momordica; Muscle Cells; PPAR gamma; Protein Domains; Rosiglitazone; Triterpenes

2021
The Yin and the Yang of CV risks in patients with diabetes.
    The American journal of managed care, 2014, Volume: 20, Issue:8 Spec No.

    Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Drug-Related Side Effects and Adverse Reactions; Heart Failure; Heart Rate; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Myocardial Infarction; Pioglitazone; Risk Assessment; Rosiglitazone; Safety-Based Drug Withdrawals; Stroke; Thiazolidinediones; United States; United States Food and Drug Administration

2014
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
    Drug safety, 2009, Volume: 32, Issue:5

    Topics: Administration, Oral; Adult; Adverse Drug Reaction Reporting Systems; Carbamates; Cohort Studies; Cyclohexanes; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Prescriptions; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Male; Middle Aged; Nateglinide; Phenylalanine; Pioglitazone; Piperidines; Rosiglitazone; Sex Factors; Thiazolidinediones

2009
[The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus].
    Wiener klinische Wochenschrift, 2009, Volume: 121, Issue:13-14

    Topics: Austria; Body Weight; Cohort Studies; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Detemir; Insulin Glargine; Insulin, Long-Acting; Myocardial Infarction; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retrospective Studies; Rosiglitazone; Thiazolidinediones

2009
[Detection of glimepiride and rosiglitazone from Chinese dietary supplements].
    Chudoku kenkyu : Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology, 2011, Volume: 24, Issue:1

    Topics: Aged; China; Chromatography, Liquid; Dietary Supplements; Drug Overdose; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Rosiglitazone; Sulfonylurea Compounds; Tandem Mass Spectrometry; Thiazolidinediones

2011
[Glycemic control and cardiovascular benefit: what do we know today?].
    Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:19

    Topics: Adult; Age Factors; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Early Termination of Clinical Trials; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Middle Aged; Pioglitazone; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Survival Analysis; Thiazolidinediones

2011
Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass.
    The Journal of biological chemistry, 2003, Sep-05, Volume: 278, Issue:36

    Topics: Adipose Tissue; Animals; Blotting, Southern; Blotting, Western; Female; Hypoglycemia; Insulin Resistance; Lipid Metabolism; Liver; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Recombination, Genetic; RNA; Rosiglitazone; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Triglycerides

2003
Enhanced radioiodine uptake in a patient with poorly differentiated papillary thyroid cancer after treatment with rosiglitazone.
    Clinical nuclear medicine, 2006, Volume: 31, Issue:9

    Topics: Cell Differentiation; Female; Humans; Hypoglycemia; Iodine Radioisotopes; Middle Aged; Neoplasm Metastasis; Peroxisome Proliferator-Activated Receptors; Radionuclide Imaging; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Neoplasms

2006